Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.17.3.2 (
xanthine oxidase
)
8,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nuclear receptor peroxisome proliferator-activated receptor gamma (
PPAR gamma
) is essential for adipogenesis. Although several fatty acids and their derivatives are known to bind and activate
PPAR gamma
, the nature of the endogenous ligand(s) promoting the early stages of adipocyte differentiation has remained enigmatic. Previously, we showed that lipoxygenase (LOX) activity is involved in activation of
PPAR gamma
during the early stages of adipocyte differentiation. Of the seven known murine LOXs, only the unconventional LOX epidermis-type lipoxygenase 3 (eLOX3) is expressed in 3T3-L1 preadipocytes. Here, we show that forced expression of eLOX3 or addition of eLOX3 products stimulated adipogenesis under conditions that normally require an exogenous
PPAR gamma
ligand for differentiation. Hepoxilins, a group of oxidized arachidonic acid derivatives produced by eLOX3, bound to and activated
PPAR gamma
. Production of hepoxilins was increased transiently during the initial stages of adipogenesis. Furthermore, small interfering RNA-mediated or retroviral short hairpin RNA-mediated knockdown of eLOX3 expression abolished differentiation of 3T3-L1 preadipocytes. Finally, we demonstrate that
xanthine oxidoreductase
(
XOR
) and eLOX3 synergistically enhanced
PPAR gamma
-mediated transactivation. Collectively, our results indicate that hepoxilins produced by the concerted action of
XOR
and eLOX3 may function as
PPAR gamma
activators capable of promoting the early
PPAR gamma
-dependent steps in the conversion of preadipocytes into adipocytes.
...
PMID:Epidermis-type lipoxygenase 3 regulates adipocyte differentiation and peroxisome proliferator-activated receptor gamma activity. 2053 Jan 98